@FiercePharma: ICYMI: Look for orphan drugs to keep fueling M&A, Moody's says. Report | Follow @FiercePharma
@CarlyHFierce: Valeant plots big DTC push for Xifaxan while rival Actavis drug waits on DEA. More from FiercePharmaMarketing | Follow @CarlyHFierce
> GlaxoSmithKline's ($GSK) marketing blitz on the newly OTC allergy remedy Flonase has paid off, with almost $100 million in sales during its first 16 weeks on the market. Report
> Two U.S. Senators, concerned that compounding pharmacy rules would restrict use of Roche's ($RHHBY) cancer drug Avastin as a substitute for its pricier eye treatment Lucentis, have written HHS to raise the question. Report
> Johnson & Johnson ($JNJ) settled another lawsuit over Risperdal's potential to trigger breast development in boys for an undisclosed sum; two other suits have ended in decisions against J&J--at least partly--but lawyers say the litigation will continue case by case. Report
> The FDA gave priority review to Merck & Co.'s ($MRK) Keytruda as a treatment for non-small cell lung cancer, advancing the drug in its race to compete with Bristol-Myers Squibb's ($BMY) Opdivo in that disease. Report
> Novartis ($NVS) said new one-year data for its anti-inflammatory drug Cosentyx in ankylosing spondylitis will be presented at the upcoming European League Against Rheumatism meeting. Report
Medical Device News
@FierceMedDev: ICYMI: Fierce exclusive: Zimmer to cut staff, close its dental headquarters following $13B merger with Biomet. Report | Follow @FierceMedDev
@VarunSaxena2: Hospitals tell feds that they can do more to support unique device ID. Story | Follow @VarunSaxena2
@EmilyWFierce: ICYMI: Otsuka faces the music for generic Abilify, loses battle with FDA. Article | Follow @EmilyWFierce
> Prenatal Dx player Natera looks to do an up to $100M IPO to expand, move into liquid biopsy. More
> Israeli startup unveils cloud-based mobile fetal monitor. Article
Biotech News
@FierceBiotech: ICYMI yesterday: Bristol-Myers fires off a lawsuit to sideline R&D defector headed to rival AstraZeneca. Article | Follow @FierceBiotech
@JohnCFierce: Top #ASCO15 story for @FierceBiotech: Genentech's PD-L1 breakthrough star 'atezo' positioned to vault ahead on cancer. Story | Follow @JohnCFierce
@DamianFierce: Kinda feels like $JUNO Googled "CAR-T" and is gradually buying the whole first page of results. Release | Story | Follow @DamianFierce
> Regulus tanks on CEO's exit as investors fear a bad omen. Article
> Sprout's 'female Viagra' lines up for a make-or-break FDA review. Report
> With a crucial CAR-T trial looming for Cellectis, a confident André Choulika is laying it all on the line. Article
Drug Delivery News
> NeuroVive's cardiology candidate fails to meet its endpoint. Item
> Cedars-Sinai team develops delivery-Dx combo nanomed for brain cancer. More
> Reassessment of trial data at ASCO to benefit Sirtex's cancer-fighting microspheres. Report
> Novartis partners with 'robotic' pillmaker in oral biologic race. Story
> FDA approves Lilly's reformulated insulin to foster patient convenience. Article
Pharma Manufacturing News
> Myanmar Pharma plans $30M upgrade to compete with Indian imports. Item
> South Korea's Green Cross building $240M plasma plant in Canada. More
> Hospira again shipping ketorolac but U.S. faces many drug shortages. Story
> Wockhardt looks to get banned plants back online in 2016. Article
> Sources: Cipla, Lupin bid on UCB's Kremers Urban. Report
Pharma Asia News
> Leading Japan drug firms team up with AZ on parasitic disease research. News
> SK Biopharmaceuticals says Jazz-led sleep disorder PhIII candidate on the cards. Report
> Taiwan recalls Y.F. Chemical sodium chloride products on new contamination events. Article
> Cipla, Lupin in UCB U.S. generics bid as India-linked M&A heats up. More
> Novartis India gets reprieve from NPPA on fine for over-pricing drug. Story
> And Finally... Medicare paid doctors $90 billion in 2013, up 17%. Report